Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg; Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg; Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg
Проводит Servier Russia
Страница компанииDescripTion of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/atoRvastatin/Perindopril sinGle Pill Combination trEatmenT in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05764317/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 409 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (02.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 10
Критерии включения
- Obtained signed informed consent from the patient
- Patients of 18 years and older and younger than 80 years.
- Start of the treatment with SPC of amlodipine/atorvastatin/perindopril within 1 month from the Index date in accordance with the indication in Russian SmPC.
- Presence of the parameters of interest* in the medical records dated with the nearest to the start of SPC amlodipine/atorvastatin/perindopril treatment date.
- Parameters of interest include measured at rest office BP and LDL-C.
Критерии невключения
- Subjects who are unwilling or unable to provide a signed informed consent form;
- Any contraindication to the treatment with the SPC of amlodipine/atorvastatin/perindopril according to its' approved instruction for medical use in the Russian Federation;
- Concomitant use of any other ACE inhibitors, CCBs, ARBs and statins.
- Supposed low treatment adherence to the assigned SPC and the risk for poor collaboration between the patient and the investigator during the study;
- Any severe, decompensated or unstable somatic diseases or states that according to investigator discretion are life-threatening or worsen the prognosis for the patient: myocardial infarction in the past 3 months, unstable angina, current decompensation of diabetes mellitus, autoimmune or oncological diseases, severe cardiac arrhythmia, gastrointestinal disorders affecting absorbtion, severe hepatic diseases, pancreatic diseases, severe allergic reactions, connective tissue diseases etc;
- Secondary arterial hypertension;
- Alcohol or any drug abuse;
- Surgical intervention on heart or coronary vessels (i.e., heart valve(s) replacement, stent implantation or CABG), or any non-cardiological serious surgical intervention that are planned within next 3 months and may require withdrawal or changes in current therapy;
- Glomerular filtration rate less than 60 ml/min/1,72m2;
- Participating in any other clinical trial currently or during 30 days period before informed consent was signed.
Источник: ClinicalTrials.gov, NCT05764317 · запись обновлена в реестре 19 апреля 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 6
- To describe antihypertensive effectiveness of a triple single-pill combination of amlodipine, atorvastatin and perindopril at 12 weeks in patients with arterial hypertension (HTN) and dyslipidemia in the daily clinical practice. — 12 weeks
- To describe hypolipidaemic effectiveness of a triple single-pill combination of amlodipine, atorvastatin and perindopril at 12 weeks in patients with arterial hypertension (HTN) and dyslipidemia in the daily clinical practice. — 12 weeks
Цель исследования
This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of patients with HTN and dyslipidemia initiated with SPC of amlodipine/atorvastatin/perindopril in real clinical settings.
A total of 80 general practitioners and outpatient cardiologists will participate in this non-interventional study 400 patients should be included in the study.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05764317 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.